Trial reportEuropean journal of nuclear medicine and molecular imaging2004
Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.
Trial report in European journal of nuclear medicine and molecular imaging, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Pooled it
- MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis.European journal of endocrinology · 2016Pooled it
- 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation.European journal of nuclear medicine and molecular imaging · 2010Trial
- [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers.European journal of nuclear medicine and molecular imaging · 2006Trial
- Key to the Treatment of Primary Aldosteronism in Secondary Hypertension: Subtype Diagnosis.Current hypertension reports · 2023Review
- Advances in the molecular imaging of primary aldosteronism.Annals of nuclear medicine · 2023Review
- ElevatedQuantitative imaging in medicine and surgery · 2022Article
- Review
- Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism-a Review.Current hypertension reports · 2019Review
- Progress in the Management of Primary Aldosteronism.American journal of hypertension · 2018Review
- Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT.Diagnostics (Basel, Switzerland) · 2016Review
- 5th International ACC Symposium: Imaging for Diagnosis and Surveillance of Adrenal Tumors--New Advances and Reviews of Old Concepts.Hormones & cancer · 2016Review
- Radiosynthesis of [124I]iodometomidate and biological evaluation using small-animal PET.Molecular imaging and biology · 2014Article
- (18)F-FDG uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value.World journal of surgery · 2013Article
- Molecular imaging of adrenal neoplasms.Journal of surgical oncology · 2012Review
- Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.Langenbeck's archives of surgery · 2012Review
- Imaging of adrenal masses with emphasis on adrenocortical tumors.Theranostics · 2012Article
- Metomidate-based imaging of adrenal masses.Hormones & cancer · 2011Review
- FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.Hormones & cancer · 2011Review
- 11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism.Langenbeck's archives of surgery · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose(11)C-metomidate (MTO), a marker of 11beta-hydroxylase, has been suggested as a novel positron emission tomography (PET) tracer for adrenocortical imaging. Up to now, experience with this very new tracer is limited. The aims of this study were (1) to evaluate this novel tracer, (2) to point out possible advantages in comparison with( 18)F-fluorodeoxyglucose (FDG) and (3) to investigate in vivo the expression of 11beta-hydroxylase in patients with primary aldosteronism.
methodsSixteen patients with adrenal masses were investigated using both MTO and FDG PET imaging. All patients except one were operated on. Five patients had non-functioning adrenal masses, while 11 had functioning tumours(Cushing's syndrome, n=4; Conn's syndrome, n=5; phaeochromocytoma, n=2). Thirteen patients had benign disease, whereas in three cases the adrenal mass was malignant (adrenocortical cancer, n=1; malignant phaeochromocytoma, n=1; adrenal metastasis of renal cancer, n=1).
resultsMTO imaging clearly distinguished cortical from non-cortical adrenal masses (median standardised uptake values of 18.6 and 1.9, respectively, p<0.01). MTO uptake was slightly lower in patients with Cushing's syndrome than in those with Conn's syndrome, but the difference did not reach statistical significance. The expression of 11beta-hydroxylase was not suppressed in the contralateral gland of patients with Conn's syndrome, whereas in Cushing's syndrome this was clearly the case. The single patient with adrenocortical carcinoma had MTO uptake in the lower range.
conclusionMTO could not definitely distinguish between benign and malignant disease. FDG PET, however, identified clearly all three study patients with malignant adrenal lesions. We conclude: (1) MTO is an excellent imaging tool to distinguish adrenocortical and non-cortical lesions; (2) the in vivo expression of 11beta-hydroxylase is lower in Cushing's syndrome than in Conn's syndrome, and there is no suppression of the contralateral gland in primary aldosteronism; (3) for the purpose of discriminating between benign and malignant lesions, FDG is the tracer of choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.